Subcutaneous vedolizumab treatment for ulcerative colitis and Crohn‘s disease in clinical trial VISIBLE

Česká verzia

Authors: Pipek- B. ^{1 3}
Authors place of work: Centrum péče o zažívací trakt, Nemocnice AGEL Ostrava-Vítkovice a. s. ¹; II. interní klinika – gastroenterologická a geriatrická, LF UP a FN Olomouc ²; Lékařská fakulta OU, Ostrava ³
Published in the journal: Gastroent Hepatol 2020; 74(6): 558-561
Category:
doi: https://doi.org/10.48095/ccgh2020558

Zdroje

1. Lukáš M. Perspektivy bio logické léčby u idiopatických střevních zánětů. Gastroent Hepatol 2014; 68 (3): 225–229.

2. Bortlík M. Vedolizumab – nová antiintegrinová protilátka s vysokou gastrointestinální selektivitou. Gastroent Hepatol 2014; 68 (6): 481–484. doi: 10.14735/amgh2014481.

3. Sandborn WJ, Feagan BG, Rutgeerts P et al. Vedolizumab as induction and maintenance therapy for Crohn‘s disease. N Engl J Med 2013; 369 (8): 711–721. doi: 10.1056/NEJMoa1215739.

4. Sandborn WJ, Baert F, Danese S et al. Efficacy and safety of vedolizumab subcutaneous formulation in a randomized trial of patients with ulcerative colitis. Gastroenterology 2020; 158 (3): 562–572.e12. doi: 10.1053/j.gastro.2019.08.027.

5. Vermeire S, Sandborn W, Baert F et al. OP23 Efficacy and safety of vedolizumab SC in patients with moderately to severely active Crohn’s disease: results of the VISIBLE 2 study. J Crohns Colitis 2020; 14 (Suppl 1): S020–S021. doi: 10.1093/ecco-jcc/jjz203.022.

6. Loftus EV jr, Sandborn WJ, Wolf D et al. P499 Efficacy and safety of 2 or 3 vedolizumab intravenous infusions as induction therapy for ulcerative colitis and Crohn’s disease: results from VISIBLE 1 and 2. J Crohns Colitis 2019; 13 (Suppl 1): S361–S362. doi: 10.1093/ecco-jcc/ jjy222.623.

7. Sandborn WJ, Wolf D, D’haens G et al. P510 Dose escalation of subcutaneous vedolizumab in patients with ulcerative colitis: a post hoc analysis of the VISIBLE trial data. J Crohns Colitis 2020; 14 (Suppl 1): S442–S443. doi: 10.1093/ecco-jcc/jjz203.639.